| Orginal Article |
|
|
|
|
| New Advances in the Application of CAR Cell Therapy in T Cell - acute Lymphoblastic Leukemia |
| CHEN Man,WANG Ai-xian,WU Xue-ying,ZHEN Jun-yi,GONG Mei-wei,GUO Ya,WANG Hui |
| Beijing Lu Dao-pei Hospital,Beijing 100176, China |
|
|
|
Abstract Currently, cell therapy of Chimeric antigen receptors (CAR) has been widely used in the treatment of leukemia and lymphoma.CD19 and CD22 targeting CAR-T have shown significant efficacy in the treatment of recurrent and refractory acute B-lymphoblastic leukemia (RR-B-ALL) and other hematologic diseases. However, the progress is slow in the treatment of T-lineage tumors. This review introduces the current domestic and international use of CAR cell technology and CRISPR/Cas9 gene coding technology to design T-ALL CAR cell and the preliminary exploration of CAR cell immunotherapy in the treatment of T-lineage acute lymphoblastic leukaemia.
|
|
Received: 06 August 2019
Published: 20 September 2019
|
|
|
|
|
| [1] |
Iacobucci I, Mullighan C G . Genetic basis of acute lymphoblastic leukemia. J Clin Oncol, 2017,35(9):975-983.
|
|
|
| [2] |
Marks D I, Paietta E M, Moorman A V , et al. T-cell acute lymphoblastic leukemia in adults:clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood, 2009,114(51):36-45.
|
|
|
| [3] |
Goldberg J M, Silverman L B, Levy D E , et al. Childhood T-cell acute lymphoblastic leukemia:the dana-farber cancer institute acute lymphoblastic leukemia consortium experience. J Clin Oncol, 2003,21(36):16-22.
|
|
|
| [4] |
Gardner R A, Finney O, Annesley C , et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood, 2017,129(25):3322-3331.
|
|
|
| [5] |
Fry T J, Shah N N, Orentas R J , et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med, 2018,24(1):20-28.
|
|
|
| [6] |
Mamonkin M, Rouce R H, Tashiro H , et al. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood, 2015,126(8):983-992.
|
|
|
| [7] |
Brentjens R J, Santos E, Nikhamin Y , et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res, 2007,13(18 Pt 1):5426-5435.
|
|
|
| [8] |
Maus M V, June C H . Making better chimeric antigen receptors for adoptive T-cell Therapy. Clin Cancer Res, 2016,22(8):1875-1884.
|
|
|
| [9] |
Gross G, Gorochov G, Waks T , et al. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplantation Proceedings, 1989,21(1):127-130.
|
|
|
| [10] |
Kleinstiver B P, Pattanayak V, Prew M S , et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature, 2016,529(7587):490-495.
|
|
|
| [11] |
Eyquem J, Mansilla-Soto J, Giavridis T , et al. Targeting a CAR to the TRAC locus with CRISPR Cas9 enhances tumour rejection. Nature, 2017,543(7643):113-117.
|
|
|
| [12] |
MacLeod D T, Antony J, Martin A J , et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol Ther, 2017,25(4):949-961.
|
|
|
| [13] |
Morvan M G, Lanier L L . NK cells and cancer: You can teach innate cells new tricks. Nat Rev Cancer, 2016,16(1):7-19.
|
|
|
| [14] |
Li Y, Hermanson D, Moriarity B , et al. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell, 2018,23(2):181-192.
|
|
|
| [15] |
Bechan G, Lee D W, Zajonc D M , et al. Phage display generation of a novel human anti CD1a monoclonal antibody with potent cytolytic activity. Br J Haematol, 2012,159(3):299-310.
|
|
|
| [16] |
Consonni M, Dellabona P, Casorati G . Potential advantages of CD1 restricted T cell mmunotherapy in cancer. Mol Immunol, 2018,103(4):200-208.
|
|
|
| [17] |
Sánchez-Martínez, Matteo L Baroni . Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T cell acutelymphoblastic leukemia. Blood, 2019,133(21):2291-2304.
|
|
|
| [18] |
Went P, Agostinelli C ,Gallamini A,et al.Marker expression in peripheral T-cell lymphoma:a proposed clinical-pathologic prognostic score. J Clin Oncol, 2006,24(16):2472-2479.
|
|
|
| [19] |
Pui C H, Behm F G, Singh B , et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood, 1990,75(1):174-179.
|
|
|
| [20] |
Maciocia P M, Wawrzyniecka P A, Philip B , et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nature Medicine, 2017,23(12):1416-1423.
|
|
|
| [21] |
Onuoha S, Ferrari M, Bulek A , et al. Structure guided engineering of highly specific chimeric antigen receptors for the treatment of T cell lymphomas//2018 ASH Annual Meeting & Exposition, San Diego, CA , 2018.
|
|
|
| [22] |
Went P, Agostinelli C, Gallamini A , et al. Marker expression in peripheral T-cell lymphoma:a proposed clinical-pathologic prognostic score. J Clin Oncol, 2006,24(16):2472-2479.
|
|
|
| [23] |
Png Y T, Vinanica N, Kamiya T , et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv, 2017,1(25):2348-2360.
|
|
|
| [24] |
Diogo Gomes-Silva, Erden A, Pinar A A , et al. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Molecular Therapy, 2019,27(1):272-280.
|
|
|
| [25] |
Diogo Gomes-Silva, Madhuwanti S, Sandhya S , et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell alignancies. Blood, 2017,130(3):285-296.
|
|
|
| [26] |
Cooper M L, Choi J, Staser K , et al. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia, 2018,32(9):1970-1983.
|
|
|
| [27] |
You F T, Wang Y Y, Jiang L C , et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res, 2019,9(1):64-78.
|
|
|
| [28] |
Chang Y H, Connolly J, Shimasaki N , et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res, 2013,73(6):1777-1786.
|
|
|
| [29] |
Bei R, Mizejewski G , et al. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patientsto the development of an AFP-based cancer vaccine. Current Molecular Medicine, 2011,11(7):564-581.
|
|
|
| [30] |
Ruella M, Xu J, Barrett D M , et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med, 2018,24(10):1499-1503.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
